Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-20
2009-10-27
Duffy, Patricia A (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S094000, C548S335100
Reexamination Certificate
active
07608612
ABSTRACT:
The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents that provide a synergistic radiosensitizing effect. Methods of potentiating radiotherapy cancer treatment of cancers in humans, particularly of astrocytomas, are also presented, wherein a radiosensitizer composition is administered and radiotherapy is directed to the site of the tumor. Chemotherapy regimens may also be used as adjuvant therapy.
REFERENCES:
patent: 4241060 (1980-12-01), Smithen
patent: 4371540 (1983-02-01), Lee et al.
patent: 4859763 (1989-08-01), Takayanagi et al.
patent: 5270330 (1993-12-01), Suzuki et al.
patent: 5532380 (1996-07-01), Suzuki et al.
patent: 5637568 (1997-06-01), Orsolini et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5792477 (1998-08-01), Rickey et al.
patent: 6166173 (2000-12-01), Mao et al.
patent: 6180116 (2001-01-01), Philippe et al.
patent: 6201072 (2001-03-01), Rathi et al.
patent: 6376644 (2002-04-01), Mao et al.
patent: 6699504 (2004-03-01), Rowe et al.
patent: 0 302 416 (1989-02-01), None
patent: WO 02/30472 (2002-04-01), None
Chang et al ‘Radiotherapy and Radiosensitizers in the Treatment of Glioblastoma Multiforme’ Clinical Advances in Hematology and Oncology, 5(11), p. 894-902 and 907-915, 2007.
Bruce, J., “Glioblastoma Multiforme,”eMedicine, www.emedicine/com/med/topic2692.html; Jan. 13, 2005, pp. 1-20.
Char, D., et al., “Analysis of Melanoma Cell Type in Uveal Melanoma Following Treatment Failure,”Am. J. of Ophthalmology, Oct. 2004, pp. 543- 546.
Fiets, W.E., et al., “Acute Toxicity of Concurrent Adjuvant Radiotherapy and Chemotherapy (CMF or AC) in Breast Cancer Patients: A Prospective, Comparative, Non-Randomised Study,”European Journal of Cancer, 39, 2003, pp. 1081-1088.
Hurria, A., et al., “Management of Lung Cancer in Older Adults,”CA Cancer J. Clin., 2003, vol. 53, No. 6, pp. 325-341.
Keilholz, U., et al., “A Clinical Phase I Trial of Gemcitabine and Treosulfan in Uveal Melanoma and Other Solid Tumours,”European Journal of Cancer, vol. 40, 2004, p. 2047-2052.
Lau, W.Y., “Primary Liver Tumors,”Seminars in Surgical Oncology, 2000, vol. 19, pp. 135-144.
Li, Y., et al., “Treatment of Intracranial Rat Glioma Model with Implant of Radiosensitizer and Biomodulator Drug Combined with External Beam Radiotherapy,”Int. J. Radiation Oncology Biol. Phys., vol. 58, No. 2, pp. 519- 527, 2004.
Nagarajan, K., et al., “Nitroimidazoles: Part XIX—Structure-Activity Relationships,” Indian Journal of Chemistry, Section B, vol. 23B, No. 4, Apr. 1984, pp. 342-362.
Malone, J., et al., “Disease Control, Survival, and Functional Outcome After Multimodal Treatment for Advanced-Stage Tongue Base Cancer,”Head and Neck, Jul. 2004, pp. 561-572.
Matthews, R., “Nitrohistidine; a Radiosensitizer Concentrated by Cancer Cells,” Advances in Cancer Research; 2004, p. B95, Abstract.
Martinez, A., et al., “Improvement in Dose Escalation Using the Process of Adaptive Radiotherapy Combined with Three-Dimensional Conformal or Intensity-Modulated Beams for Prostate Cancer,”Int. J. Radiation Oncology Biol. Phys., vol. 50, No. 5, 2001, pp. 1226-1234.
Pawlik, T., et al., “Malignant Melanoma: Current State of Primary and Adjuvant Treatment,”Critical Reviews in Oncology/Hematology, vol. 45, 2003, pp. 245-264.
Reynolds, P, et al., “Treatment of Skin Malignancies,”The Journal of Family Practice, vol. 52, No. 6, Jun. 2003, pp. 456-458.
Seidenfeld, J., et al., “Radiofrequency Ablation of Unresectable Primary Liver Cancer,”J. Am. Coll. Surg., 2002, pp. 813-828.
Tautz, W., et al., “Nitrohistidines and Nitrohistamines,” Journal of Medicinal Chemistry, Jun. 1973, vol. 16, No. 6, pp. 705-707.
Trout, G., “Synthesis of Some Histidine Analogs and Their Effects on the Growth of a Histidine-Requiring Mutant of Leuconostoc Mesenteroides,” Journal of Medicinal Chemistry, vol. 15, No. 12, 1972, pp. 1259-1261.
Ercal Nuran
Matthews Richard H.
Zand Robert
Duffy Patricia A
Matthews Richard H.
Stone Christopher R
Sunstein Kann Murphy & Timbers LLP
LandOfFree
Radiosensitizer formulations and methods for use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiosensitizer formulations and methods for use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiosensitizer formulations and methods for use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133728